Copyright
©The Author(s) 2020.
World J Gastroenterol. Nov 7, 2020; 26(41): 6455-6474
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6455
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6455
Table 1 Patient characteristics associated with the included moderate to severe Crohn’s disease patients in real-world study
IMT, n = 295 | CMT, n = 130 | P value | |||
Patient characteristics | Mean/% | SD | Mean/% | SD | |
Demographics | |||||
Male proportion | 72.2% | 64.6% | 0.125 | ||
Age in yr | 34.1 | 10.9 | 37.2 | 11.2 | 0.004b |
BMI range | |||||
< 18.5 | 32.8% | 40.0% | 0.162 | ||
18.5-23.9 | 56.0% | 53.8% | 0.689 | ||
≥ 24 | 10.4% | 6.2% | 0.165 | ||
Lifestyle | |||||
Non-smoker | 85.7% | 87.7% | 0.592 | ||
Non-drinker | 81.9% | 88.5% | 0.093 | ||
Marital status | |||||
Unmarried | 43.2% | 32.3% | 0.037a | ||
Married | 56.0% | 67.7% | 0.026a | ||
Employment status | |||||
Student | 13.5% | 7.7% | 0.090 | ||
Full-time | 59.1% | 54.6% | 0.401 | ||
Part-time | 2.7% | 2.3% | 0.816 | ||
Unemployed | 6.9% | 1.5% | 0.023a | ||
Farmer | 1.5% | 1.5% | 0.996 | ||
Retired | 3.9% | 4.6% | 0.724 | ||
Unknown | 5.8% | 18.5% | < 0.001 | ||
Missing | 6.6% | 9.2% | 0.345 | ||
Disease site at diagnosis | |||||
Distal colon | 52.9% | 34.1% | < 0.001 | ||
Terminal ileum | 19.5% | 48.8% | < 0.001 | ||
Colon | 9.7% | 10.9% | 0.729 | ||
Upper gastrointestinal and back colon | 4.3% | 3.1% | 0.572 | ||
Upper gastrointestinal and ileum end | 4.7% | 0.8% | 0.045a | ||
Upper gastrointestinal tract | 0.0% | 0.8% | 0.158 | ||
Previous surgery | 29.0% | 30.0% | 0.831 | ||
Previous complication | |||||
Perianal abscess | 27.4% | 13.8% | 0.003b | ||
Intestinal fistula | 36.3% | 14.6% | < 0.001 | ||
Intestinal obstruction | 18.1% | 13.1% | 0.203 | ||
Extra-intestinal manifestation | |||||
Aphthous stomatitis | 8.9% | 3.8% | 0.070 | ||
Joint pain | 3.1% | 3.1% | 0.995 | ||
Comorbidities | |||||
Gallbladder diseases | 3.9% | 5.4% | 0.488 | ||
Chronic hepatitis B | 3.1% | 8.5% | 0.020a | ||
Lung nodes | 3.9% | 2.3% | 0.421 | ||
Gastroenteritis | 1.5% | 4.6% | 0.071 |
- Citation: Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474
- URL: https://www.wjgnet.com/1007-9327/full/v26/i41/6455.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i41.6455